Multi-strain Probiotic in the Management of IBS-D

Background: Accumulating evidence supports the view that an imbalance of gut bacteria contributes to IBS, and that increasing the mass of beneficial species may reduce the numbers of pathogenic bacteria and help alleviate symptoms.

Methods: In this double-blind trial 360 adult patients with moderate-to-severe symptomatic diarrhea-predominant IBS (IBS-D) were randomized to treatment with the multi-strain probiotic (Bio-Kult®; 14 different bacterial strains; 8 billion colony-forming units per day) or placebo for 16 weeks. The change in severity and frequency of abdominal pain was the primary outcome measure.

Inclusion criteria

• Diagnosed case of IBS using Rome III criteria
• Absence of red flag sign: anemia, fever, wt loss, per rectal bleeding, nocturnal frequency, family history of inflammatory bowel disease (IBD), cancer
• Age 18-55 years
• No probiotics used in prior 3 months.
• Agreed not to start any other drug unless clinically indicated.
• No antibiotics in previous 2 months of enrolment.

Exclusion criteria

• Age<18 or >55 years
• Previous treatment with probiotics within last 3 months
• Pregnant or lactating females
• Concurrent severe illness (Uncontrolled diabetes mellitus, Renal Dysfunction, Liver disease, hyper and hypothyroidism)
• Chronic organic bowel disorders e.g. inflammatory bowel diseases, tuberculosis, Diverticular disease etc
• Any previous gastrointestinal surgery